You want to quash 'Low-T' overprescription, FDA? Quash DTC ads, experts urge

After warning that casual use of testosterone meds can cause heart attack and stroke, the FDA has finally put its foot down to curb overprescribing of the drugs. But some say the agency needs to go further--and that means putting the kibosh on the marketing campaigns that have helped swell their market past $2 billion. More from FiercePharmaMarketing

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.